Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

ANABREZ ANASTROZOLE FILM COATED TABLET USP 1MG [SIN16144P]

Active ingredients: ANASTROZOLE

View product's general information
Last updated on 9 October 2026

Product Info

ANABREZ ANASTROZOLE FILM COATED TABLET USP 1MG

[SIN16144P]

Product information

Active Ingredient and Strength

ANASTROZOLE - 1 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

SUN PHARMACEUTICAL INDUSTRIES LIMITED - INDIA

Registration Number

SIN16144P

Licence Holder

RANBAXY (MALAYSIA) SDN. BHD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

L02BG03

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATIONS

ANABREZ is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer.

Treatment of advanced breast cancer in postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Efficacy has not been demonstrated in oestrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen.

Dosing

DOSE AND METHOD OF ADMINISTRATION

Adults including elderly: One 1mg tablet to be taken orally once a day

Special Populations

Children: Not recommended for use in children

Renal Impairment: No dose change is recommended in patients with mild or moderate renal impairment

Hepatic Impairment: No dose change is recommended in patients with mild hepatic disease.

For early disease, the recommended duration of treatment should be 5 years.

Method of Administration
For oral use

Contraindications

CONTRAINDICATIONS

Anastrozole is contraindicated in:

  • premenopausal women

  • pregnant or lactating women

  • patients with severe renal impairment (creatinine clearance less than 20ml/min)

  • patients with moderate or severe hepatic disease

  • patients with known hypersensitivity to anastrozole or to any of the excipients

Oestrogen-containing therapies should not be co-administered with anastrozole as they would negate its pharmacological action.

Concurrent tamoxifen therapy (see DRUG INTERACTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)